Androcur® (Cyproterone Acetate) and Meningioma Development: a Genotype-environment Association Study

Inclusion Criteria:

• Age ⩾18 years;
• Non-opposition opinion obtained during the first phone call at the beginning of thestudy;
• Covered by the french social security scheme. For the group 1:
• Meningioma diagnosed by medical imaging and confirmed histologically if surgeryoccurred;
• Cyproterone acetate taken for at least 6 months, 25 mg par day and 20 day by month (cumulated dose ⩾ 3 000mg). For the group 2:
• Cyproterone acetate taken for at least 5 years with dose of 50 mg per day and 20 dayby month, or a cumulated dose corresponding to a longer period (⩾ 30 000mg);
• Normal result of RMI examination performed after at least 5 years treatment bycyproterone acetate. For the group 3 :
• Subject who has never taken cyproterone acetate;
• Meningioma diagnosed by medical imaging examination and confirmed histologically ifsurgery occured. For the group 4 :
• Subject who has never taken cyproterone acetate;
• Subject never diagnosed with meningioma.

Exclusion Criteria:

• Subject under tutoraship;
• Subject refusal;
• Communication difficulties such as: language barriers, serious problems of hearingwithout a hearing instrument, cognitive troubles... ;
• Foreign subject under AME scheme (a french social system).